J Menopausal Med.  2014 Aug;20(2):47-51. 10.6118/jmm.2014.20.2.47.

Gaps in Menopause Knowledge

• Yum SK
• Kim T

• KMID: 2325441
• DOI: http://doi.org/10.6118/jmm.2014.20.2.47

Abstract

The average middle aged woman goes through a volatile period of endocrine fluctuations as she passes through menopause and the stages that precede and follow it. Ovarian hormones are steroid hormones. They readily cross the cell and nuclear membranes and influence transcription of numerous genes. Such influences are tissue specific and state specific. In short, changes in ovarian hormones mean that a women will experience changes in her entire body systems. When an individual woman's constitutional factors, pathologic states, medications, environmental exposures are taken into consideration, the integrated changes become too complex to predict. Inter-study sampling differences with the complexities in the backdrop may have led to conflicting conclusions in menopause research. This paper reviews some of the controversies in the care of menopausal women.

Keyword

Health knowledge attitudes practice; Hormones; Menopause; Women's health

MeSH Terms

Environmental Exposure
Female
Humans
Menopause*
Middle Aged
Nuclear Envelope
Women's Health

Reference

1. Beato M, Sánchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996; 17:587–609.

2. Rubinow DR, Schmidt PJ, Meltzer-Brody S, Harsh VL. The neurobiology of menstrual cycle-related mood disorders. In : Charney DS, Nestler EJ, editors. Neurobiology of mental illness. 3rd ed. New York, NY: Oxford University Press;2009. p. 544–555.

3. Arca M, Vega GL, Grundy SM. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. JAMA. 1994; 271:453–459.

4. Nakajima K. S-POLIS Group. Sex-related differences in response of plasma lipids to simvastatin: the Saitama Postmenopausal Lipid Intervention Study. Clin Ther. 1999; 21:2047–2057.

5. Wassertheil-Smoller S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B, et al. The Women's Health Initiative (WHI). Depression and cardiovascular sequelae in postmenopausal women. Arch Intern Med. 2004; 164:289–298.

6. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther. 2011; 90:133–142.

7. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 2001; 358:351–355.

8. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012; 172:144–152.

9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002; 288:321–333.

10. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349:523–534.

11. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004; 292:1573–1580.

12. Petersen M. Wyeth stock falls 24% after report. New York, NY: The New York Times;2002. 07. 10. cited by 2014 Mar 6. Available from: http://www.nytimes.com/2002/07/10/us/wyeth-stock-falls-24-after-report.html.

13. Feeley J. Pfizer paid $896 million in prempro settlements. New York, NY: Bloomberg;2012. 06. 19. cited by 2014 Mar 6. Available from: http://www.bloomberg.com/news/2012-06-19/pfizer-paid-896-million-in-prempro-accords-filing-shows-1-.html.

14. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356:2591–2602.

15. Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med. 2007; 356:2639–2641.

16. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006; 15:35–44.

17. Haan MN, Klein R, Klein BE, Deng Y, Blythe LK, Seddon JM, et al. Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study. Arch Ophthalmol. 2006; 124:988–992.

18. Newman-Casey PA, Talwar N, Nan B, Musch DC, Pasquale LR, Stein JD. The potential association between postmenopausal hormone use and primary open-angle glaucoma. JAMA Ophthalmol. 2014; 132:298–303.

19. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289:2651–2662.

20. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289:2663–2672.

21. Craig MC, Murphy DG. Estrogen therapy and Alzheimer's dementia. Ann N Y Acad Sci. 2010; 1205:245–253.

22. Kim T. The effects of estrogen on the cognitive function and dementia. J Korean Soc Menopause. 2006; 12:103–112.

23. Carcaillon L, Brailly-Tabard S, Ancelin ML, Rouaud O, Dartigues JF, Guiochon-Mantel A, et al. High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women. Neurology. 2014; 82:504–511.

24. Foster EA, Franks DW, Mazzi S, Darden SK, Balcomb KC, Ford JK, et al. Adaptive prolonged postreproductive life span in killer whales. Science. 2012; 337:1313.

25. Pollycove R, Naftolin F, Simon JA. The evolutionary origin and significance of menopause. Menopause. 2011; 18:336–342.

26. The Organisation for Economic Co-operation and Development. OECD health data. Paris, Fr: The Organisation for Economic Co-operation and Development;2013. cited by 2014 Mar 6. Available from: http://www.oecd.org/health/.

27. Yum SK, Yoon BK, Lee BI, Park HM, Kim T. Epidemiologic survey of menopausal and vasomotor symptoms in Korean women. J Korean Soc Menopause. 2012; 18:147–154.